Non‐natural MUC1 Glycopeptide Homogeneous Cancer Vaccine with Enhanced Immunogenicity and Therapeutic Activity

  1. Guerreiro, Ana 3
  2. Compañón, Ismael 1
  3. Lazaris, Foivos S. 1
  4. Labão-Almeida, Carlos 3
  5. Oroz, Paula 1
  6. Ghirardello, Mattia 1
  7. Marques, Marta C. 3
  8. Corzana, Francisco 1
  9. Bernardes, Gonçalo J. L. 2
  1. 1 Universidad de La Rioja
    info

    Universidad de La Rioja

    Logroño, España

    ROR https://ror.org/0553yr311

  2. 2 University of Cambridge
    info

    University of Cambridge

    Cambridge, Reino Unido

    ROR https://ror.org/013meh722

  3. 3 Universidade de Lisboa
    info

    Universidade de Lisboa

    Lisboa, Portugal

    ROR https://ror.org/01c27hj86

Erakutsi afiliazioak +
Aldizkaria:
Angewandte Chemie International Edition

ISSN: 1433-7851,  1521-3773

Argitalpen urtea: 2024

Mota: Artikulua

beta Ver similares en nube de resultados
DOI: 10.1002/ANIE.202411009 GOOGLE SCHOLAR lock_openSarbide irekia editor

Beste argitalpen batzuk: Angewandte Chemie International Edition

Laburpena

Glycopeptides derived from the glycoprotein mucin-1 (MUC1) have shown potential as tumor-associated antigens for cancer vaccine development. However, their low immunogenicity and non-selective conjugation to carriers present significant challenges for the clinical efficacy of MUC1-based vaccines. Here, we introduce a novel vaccine candidate based on a structure-guided design of an artificial antigen derived from MUC1 glycopeptide. This engineered antigen contains two non-natural amino acids and has an α-S-glycosidic bond, where sulfur replaces the conventional oxygen atom linking the peptide backbone to the sugar N-acetylgalactosamine. The glycopeptide is then specifically conjugated to the immunogenic protein carrier CRM197 (Cross-Reactive Material 197), a protein approved for human use. Conjugation involves selective reduction and re-bridging of a disulfide in CRM197, allowing the attachment of a single copy of MUC1. This strategy results in a chemically defined vaccine while maintaining both the structural integrity and immunogenicity of the protein carrier. The vaccine elicits a robust Th1-like immune response in mice and generates antibodies capable of recognizing human cancer cells expressing tumor-associated MUC1. When tested in mouse models of colon adenocarcinoma and pancreatic cancer, the vaccine is effective both as a prophylactic and therapeutic use, significantly delaying tumor growth. In therapeutic applications, improved outcomes were….